Role of erythropoietin in anemia after heart transplantation
Anemia after heart transplantation is common; however, there are scant data on etiology and treatment. This study evaluates type of anemia and the effects of erythropoietin therapy. In 37 anemic heart transplant recipients (31 male/59.1 ± 10.3 years/hemoglobin < 12.0g/dl), complete anemia work-up...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2006-10, Vol.112 (3), p.341-347 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 347 |
|---|---|
| container_issue | 3 |
| container_start_page | 341 |
| container_title | International journal of cardiology |
| container_volume | 112 |
| creator | Gleissner, Christian A. Klingenberg, Roland Staritz, Peter Koch, Achim Ehlermann, Philipp Wiggenhauser, Alfred Dengler, Thomas J. |
| description | Anemia after heart transplantation is common; however, there are scant data on etiology and treatment. This study evaluates type of anemia and the effects of erythropoietin therapy.
In 37 anemic heart transplant recipients (31 male/59.1
±
10.3 years/hemoglobin <
12.0g/dl), complete anemia work-up was performed including erythropoietin determination. For three months, 12 anemic patients with renal failure (9 male/64.1
±
13.6 years) were treated with 1–3
×
4000 IU of epoietin beta/week; treatment endpoints were hemoglobin levels and quality of life as determined by questionnaire.
In 31 patients no other cause of anemia than renal insufficiency (mean creatinine 1.9
±
0.9 mg/dl, mean calculated GFR 50.8
±
21.5 ml/min, no hemodialysis) was found; in 93.5% of these patients with renal insufficiency, measured erythropoietin levels were markedly lower than predicted [Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81(4):1067-1076.]. There was an inverse correlation of hemoglobin levels with serum creatinine/creatinine clearance and a strong trend for inverse correlation of erythropoietin levels. All 12 patients treated with erythropoietin showed a significant increase in hemoglobin levels after three months returning to pre-treatment values within 3 months of cessation of therapy (before study 10.8
±
1.1 g/dl, end of study 14.1
±
1.7 g/dl, three months after end of study 11.6
±
2.1 g/dl;
p
<
0.005). Quality of life was significantly improved in eight patients (75%).
Anemia after heart transplantation is associated with moderate renal failure and low erythropoietin levels in most patients. Erythropoietin therapy resulted in increased hemoglobin levels in all and improved quality of life in 75% of patients. Erythropoietin may be a superior marker of functional renal impairment after heart transplantation; its therapeutic substitution allows effective anemia management and improves quality of life. |
| doi_str_mv | 10.1016/j.ijcard.2005.10.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68875473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527305012362</els_id><sourcerecordid>68875473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-e526462f1878362099e6867ab5af3bb3bf30b75da882f72402ac1781b9892c783</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobk7_gUhv9K4zSdt8gAgy_IKBIHod0vSEZXTNTDJh_96MDXYnBAKH5z158yB0TfCUYMLul1O3NDp0U4pxk0dTjPkJGhPB65Lwpj5F44zxsqG8GqGLGJcY41pKcY5GhFVYctaM0cOn76HwtoCwTYvg195BckORjx5g5XShbYJQLECHVKSgh7ju9ZB0cn64RGdW9xGuDvcEfb88f83eyvnH6_vsaV6aSuJUQkNZzajN1UTFKJYSmGBct422VdtWra1wy5tOC0EtpzWm2hAuSCuFpCZnJuhuv3cd_M8GYlIrFw30uQj4TVRMiPxhXmWw3oMm-BgDWLUObqXDVhGsdtbUUu2tqZ213TRby7Gbw_5Nu4LuGDpoysDtAdDR6N5mDcbFIydI3XC5e_9xz0G28esgqGgcDAY6F8Ak1Xn3f5M_3lKLlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68875473</pqid></control><display><type>article</type><title>Role of erythropoietin in anemia after heart transplantation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gleissner, Christian A. ; Klingenberg, Roland ; Staritz, Peter ; Koch, Achim ; Ehlermann, Philipp ; Wiggenhauser, Alfred ; Dengler, Thomas J.</creator><creatorcontrib>Gleissner, Christian A. ; Klingenberg, Roland ; Staritz, Peter ; Koch, Achim ; Ehlermann, Philipp ; Wiggenhauser, Alfred ; Dengler, Thomas J.</creatorcontrib><description>Anemia after heart transplantation is common; however, there are scant data on etiology and treatment. This study evaluates type of anemia and the effects of erythropoietin therapy.
In 37 anemic heart transplant recipients (31 male/59.1
±
10.3 years/hemoglobin <
12.0g/dl), complete anemia work-up was performed including erythropoietin determination. For three months, 12 anemic patients with renal failure (9 male/64.1
±
13.6 years) were treated with 1–3
×
4000 IU of epoietin beta/week; treatment endpoints were hemoglobin levels and quality of life as determined by questionnaire.
In 31 patients no other cause of anemia than renal insufficiency (mean creatinine 1.9
±
0.9 mg/dl, mean calculated GFR 50.8
±
21.5 ml/min, no hemodialysis) was found; in 93.5% of these patients with renal insufficiency, measured erythropoietin levels were markedly lower than predicted [Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81(4):1067-1076.]. There was an inverse correlation of hemoglobin levels with serum creatinine/creatinine clearance and a strong trend for inverse correlation of erythropoietin levels. All 12 patients treated with erythropoietin showed a significant increase in hemoglobin levels after three months returning to pre-treatment values within 3 months of cessation of therapy (before study 10.8
±
1.1 g/dl, end of study 14.1
±
1.7 g/dl, three months after end of study 11.6
±
2.1 g/dl;
p
<
0.005). Quality of life was significantly improved in eight patients (75%).
Anemia after heart transplantation is associated with moderate renal failure and low erythropoietin levels in most patients. Erythropoietin therapy resulted in increased hemoglobin levels in all and improved quality of life in 75% of patients. Erythropoietin may be a superior marker of functional renal impairment after heart transplantation; its therapeutic substitution allows effective anemia management and improves quality of life.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2005.10.007</identifier><identifier>PMID: 16309765</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Aged ; Anemia ; Anemia - blood ; Anemia - drug therapy ; Anemia - etiology ; Anemias. Hemoglobinopathies ; Biological and medical sciences ; Cardiology. Vascular system ; Creatinine ; Creatinine - blood ; Diseases of red blood cells ; Erythropoietin ; Erythropoietin - blood ; Erythropoietin - therapeutic use ; Female ; Heart Transplantation ; Hematologic and hematopoietic diseases ; Hemoglobin ; Humans ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Pilot Projects ; Postoperative Complications - drug therapy ; Quality of Life ; Recombinant Proteins ; Regression Analysis ; Renal failure ; Renal Insufficiency - complications</subject><ispartof>International journal of cardiology, 2006-10, Vol.112 (3), p.341-347</ispartof><rights>2005 Elsevier Ireland Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-e526462f1878362099e6867ab5af3bb3bf30b75da882f72402ac1781b9892c783</citedby><cites>FETCH-LOGICAL-c390t-e526462f1878362099e6867ab5af3bb3bf30b75da882f72402ac1781b9892c783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2005.10.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18145793$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16309765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gleissner, Christian A.</creatorcontrib><creatorcontrib>Klingenberg, Roland</creatorcontrib><creatorcontrib>Staritz, Peter</creatorcontrib><creatorcontrib>Koch, Achim</creatorcontrib><creatorcontrib>Ehlermann, Philipp</creatorcontrib><creatorcontrib>Wiggenhauser, Alfred</creatorcontrib><creatorcontrib>Dengler, Thomas J.</creatorcontrib><title>Role of erythropoietin in anemia after heart transplantation</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Anemia after heart transplantation is common; however, there are scant data on etiology and treatment. This study evaluates type of anemia and the effects of erythropoietin therapy.
In 37 anemic heart transplant recipients (31 male/59.1
±
10.3 years/hemoglobin <
12.0g/dl), complete anemia work-up was performed including erythropoietin determination. For three months, 12 anemic patients with renal failure (9 male/64.1
±
13.6 years) were treated with 1–3
×
4000 IU of epoietin beta/week; treatment endpoints were hemoglobin levels and quality of life as determined by questionnaire.
In 31 patients no other cause of anemia than renal insufficiency (mean creatinine 1.9
±
0.9 mg/dl, mean calculated GFR 50.8
±
21.5 ml/min, no hemodialysis) was found; in 93.5% of these patients with renal insufficiency, measured erythropoietin levels were markedly lower than predicted [Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81(4):1067-1076.]. There was an inverse correlation of hemoglobin levels with serum creatinine/creatinine clearance and a strong trend for inverse correlation of erythropoietin levels. All 12 patients treated with erythropoietin showed a significant increase in hemoglobin levels after three months returning to pre-treatment values within 3 months of cessation of therapy (before study 10.8
±
1.1 g/dl, end of study 14.1
±
1.7 g/dl, three months after end of study 11.6
±
2.1 g/dl;
p
<
0.005). Quality of life was significantly improved in eight patients (75%).
Anemia after heart transplantation is associated with moderate renal failure and low erythropoietin levels in most patients. Erythropoietin therapy resulted in increased hemoglobin levels in all and improved quality of life in 75% of patients. Erythropoietin may be a superior marker of functional renal impairment after heart transplantation; its therapeutic substitution allows effective anemia management and improves quality of life.</description><subject>Aged</subject><subject>Anemia</subject><subject>Anemia - blood</subject><subject>Anemia - drug therapy</subject><subject>Anemia - etiology</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Creatinine</subject><subject>Creatinine - blood</subject><subject>Diseases of red blood cells</subject><subject>Erythropoietin</subject><subject>Erythropoietin - blood</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Heart Transplantation</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Pilot Projects</subject><subject>Postoperative Complications - drug therapy</subject><subject>Quality of Life</subject><subject>Recombinant Proteins</subject><subject>Regression Analysis</subject><subject>Renal failure</subject><subject>Renal Insufficiency - complications</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LwzAUhoMobk7_gUhv9K4zSdt8gAgy_IKBIHod0vSEZXTNTDJh_96MDXYnBAKH5z158yB0TfCUYMLul1O3NDp0U4pxk0dTjPkJGhPB65Lwpj5F44zxsqG8GqGLGJcY41pKcY5GhFVYctaM0cOn76HwtoCwTYvg195BckORjx5g5XShbYJQLECHVKSgh7ju9ZB0cn64RGdW9xGuDvcEfb88f83eyvnH6_vsaV6aSuJUQkNZzajN1UTFKJYSmGBct422VdtWra1wy5tOC0EtpzWm2hAuSCuFpCZnJuhuv3cd_M8GYlIrFw30uQj4TVRMiPxhXmWw3oMm-BgDWLUObqXDVhGsdtbUUu2tqZ213TRby7Gbw_5Nu4LuGDpoysDtAdDR6N5mDcbFIydI3XC5e_9xz0G28esgqGgcDAY6F8Ak1Xn3f5M_3lKLlA</recordid><startdate>20061010</startdate><enddate>20061010</enddate><creator>Gleissner, Christian A.</creator><creator>Klingenberg, Roland</creator><creator>Staritz, Peter</creator><creator>Koch, Achim</creator><creator>Ehlermann, Philipp</creator><creator>Wiggenhauser, Alfred</creator><creator>Dengler, Thomas J.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061010</creationdate><title>Role of erythropoietin in anemia after heart transplantation</title><author>Gleissner, Christian A. ; Klingenberg, Roland ; Staritz, Peter ; Koch, Achim ; Ehlermann, Philipp ; Wiggenhauser, Alfred ; Dengler, Thomas J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-e526462f1878362099e6867ab5af3bb3bf30b75da882f72402ac1781b9892c783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Anemia</topic><topic>Anemia - blood</topic><topic>Anemia - drug therapy</topic><topic>Anemia - etiology</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Creatinine</topic><topic>Creatinine - blood</topic><topic>Diseases of red blood cells</topic><topic>Erythropoietin</topic><topic>Erythropoietin - blood</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Heart Transplantation</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Pilot Projects</topic><topic>Postoperative Complications - drug therapy</topic><topic>Quality of Life</topic><topic>Recombinant Proteins</topic><topic>Regression Analysis</topic><topic>Renal failure</topic><topic>Renal Insufficiency - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gleissner, Christian A.</creatorcontrib><creatorcontrib>Klingenberg, Roland</creatorcontrib><creatorcontrib>Staritz, Peter</creatorcontrib><creatorcontrib>Koch, Achim</creatorcontrib><creatorcontrib>Ehlermann, Philipp</creatorcontrib><creatorcontrib>Wiggenhauser, Alfred</creatorcontrib><creatorcontrib>Dengler, Thomas J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gleissner, Christian A.</au><au>Klingenberg, Roland</au><au>Staritz, Peter</au><au>Koch, Achim</au><au>Ehlermann, Philipp</au><au>Wiggenhauser, Alfred</au><au>Dengler, Thomas J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of erythropoietin in anemia after heart transplantation</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2006-10-10</date><risdate>2006</risdate><volume>112</volume><issue>3</issue><spage>341</spage><epage>347</epage><pages>341-347</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Anemia after heart transplantation is common; however, there are scant data on etiology and treatment. This study evaluates type of anemia and the effects of erythropoietin therapy.
In 37 anemic heart transplant recipients (31 male/59.1
±
10.3 years/hemoglobin <
12.0g/dl), complete anemia work-up was performed including erythropoietin determination. For three months, 12 anemic patients with renal failure (9 male/64.1
±
13.6 years) were treated with 1–3
×
4000 IU of epoietin beta/week; treatment endpoints were hemoglobin levels and quality of life as determined by questionnaire.
In 31 patients no other cause of anemia than renal insufficiency (mean creatinine 1.9
±
0.9 mg/dl, mean calculated GFR 50.8
±
21.5 ml/min, no hemodialysis) was found; in 93.5% of these patients with renal insufficiency, measured erythropoietin levels were markedly lower than predicted [Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81(4):1067-1076.]. There was an inverse correlation of hemoglobin levels with serum creatinine/creatinine clearance and a strong trend for inverse correlation of erythropoietin levels. All 12 patients treated with erythropoietin showed a significant increase in hemoglobin levels after three months returning to pre-treatment values within 3 months of cessation of therapy (before study 10.8
±
1.1 g/dl, end of study 14.1
±
1.7 g/dl, three months after end of study 11.6
±
2.1 g/dl;
p
<
0.005). Quality of life was significantly improved in eight patients (75%).
Anemia after heart transplantation is associated with moderate renal failure and low erythropoietin levels in most patients. Erythropoietin therapy resulted in increased hemoglobin levels in all and improved quality of life in 75% of patients. Erythropoietin may be a superior marker of functional renal impairment after heart transplantation; its therapeutic substitution allows effective anemia management and improves quality of life.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>16309765</pmid><doi>10.1016/j.ijcard.2005.10.007</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2006-10, Vol.112 (3), p.341-347 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68875473 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Anemia Anemia - blood Anemia - drug therapy Anemia - etiology Anemias. Hemoglobinopathies Biological and medical sciences Cardiology. Vascular system Creatinine Creatinine - blood Diseases of red blood cells Erythropoietin Erythropoietin - blood Erythropoietin - therapeutic use Female Heart Transplantation Hematologic and hematopoietic diseases Hemoglobin Humans Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Pilot Projects Postoperative Complications - drug therapy Quality of Life Recombinant Proteins Regression Analysis Renal failure Renal Insufficiency - complications |
| title | Role of erythropoietin in anemia after heart transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A35%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20erythropoietin%20in%20anemia%20after%20heart%20transplantation&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Gleissner,%20Christian%20A.&rft.date=2006-10-10&rft.volume=112&rft.issue=3&rft.spage=341&rft.epage=347&rft.pages=341-347&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2005.10.007&rft_dat=%3Cproquest_cross%3E68875473%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68875473&rft_id=info:pmid/16309765&rft_els_id=S0167527305012362&rfr_iscdi=true |